News
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Medicines and Healthcare products Regulatory Agency ...
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
KalVista Pharmaceuticals has received marketing authorization in the U.K. for Ekterly, its treatment for hereditary angioedema attacks.
9d
GlobalData on MSNFDA approves KalVista’s Ekterly for hereditary angioedemaThe US Food and Drug Administration (FDA) has approved KalVista Pharmaceuticals' Ekterly (sebetralstat) as the first and only ...
After facing an unexpected regulatory delay last month, KalVista Pharmaceuticals has leapt into the commercial realm with the ...
EKTERLY to be added to the Orphan Register and awarded 10 years of market exclusivity KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Medicines and Healthcare products Regulator ...
The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...
Ekterly’s road to approval was not a smooth one. Last month, the FDA informed KalVista it would not meet its PDUFA date due ...
KalVista Pharma has finally received FDA approval for its oral kallikrein inhibitor sebetralstat, becoming the first ...
FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.
KalVista Pharmaceuticals Inc, a clinical-stage pharmaceutical company listed on the S&P 500, has achieved a significant ...
Ekterly becomes the first FDA-approved oral on-demand treatment for hereditary angioedema in patients aged 12 years and older ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results